FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wolfgang Kern

Research Profile

Disorders

Physiology

Mutation

Procedures

Chemicals & Drugs

Occupations

Cytogenetics

Anatomy

Chromosomes, Human, Pair 21

Co-author Network

Publications

TOP 3
Susanne Schnittger; Wolfgang Kern; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Melanie Zenger; Andreas Hochhaus; Dietrich W Beelen; Michael Uppenkamp; Mathias Rummel; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Tamara Alpermann; Susanne Schnittger; Claudia Haferlach
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wolfgang Kern (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Susanne Schnittger; Wolfgang Kern; Tamara Alpermann; Ulrike Bacher; Claudia Haferlach; Torsten Haferlach
Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Haematologica 2011;96(12):1799-807.
2011: Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Melanie Zenger; Andreas Hochhaus; Dietrich W Beelen; Michael Uppenkamp; Mathias Rummel; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
British journal of haematology 2011;152(6):713-20.
2010: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Tamara Alpermann; Susanne Schnittger; Claudia Haferlach
Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.
Cancer genetics and cytogenetics 2010;203(2):169-75.
2010: Ulrike Bacher; Torsten Haferlach; Tamara Alpermann; Melanie Zenger; Nicolaus Kröger; Dietrich W Beelen; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(12):1649-57.
2010: Wolfgang Kern; Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Torsten Haferlach
The role of multiparameter flow cytometry for disease monitoring in AML.
Best practice & research. Clinical haematology 2010;23(3):379-90.
2010: Evgeny Klyuchnikov; Svetlana Asenova; Wolfgang Kern; Gökhan Kilinc; Francis Ayuk; Bettina Wiedemann; Michael V Lioznov; Petra Freiberger; Yuriy Zalyalov; Axel R Zander; Nicolaus Kröger; Ulrike Bacher
Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
Leukemia & lymphoma 2010;51(8):1450-63.
2009: Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Tamara Weiss; Torsten Haferlach; Claudia Haferlach
Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Annals of hematology 2009;88(12):1207-13.
2009: Wolfgang Kern; Frank Dicker; Susanne Schnittger; Claudia Haferlach; Torsten Haferlach
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Cytometry. Part B, Clinical cytometry 2009;76(6):385-93.
2009: Susanne Schnittger; Wolfgang Kern; Claudia Tschulik; Tamara Weiss; Frank Dicker; Brunangelo Falini; Claudia Haferlach; Torsten Haferlach
Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
Blood 2009;114(11):2220-31.
2009: Torsten Haferlach; A Kohlmann; H-U Klein; C Ruckert; M Dugas; P M Williams; Wolfgang Kern; Susanne Schnittger; Ulrike Bacher; H Löffler; Claudia Haferlach
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features.
Leukemia 2009;23(5):934-43.
2009: Frank Dicker; H Herholz; Susanne Schnittger; A Nakao; N Patten; L Wu; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Leukemia 2009;23(1):117-24.
2008: Claudia Haferlach; Frank Dicker; H Herholz; Susanne Schnittger; Wolfgang Kern; Torsten Haferlach
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype.
Leukemia 2008;22(8):1539-41.
2008: Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.
Blood 2008;111(5):2527-37.
2008: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; R Dengler; A Kröber; Wolfgang Kern; Torsten Haferlach
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
Leukemia 2008;22(2):453-5.
2008: Wolfgang Kern; Claudia Haferlach; Torsten Haferlach; Susanne Schnittger
Monitoring of minimal residual disease in acute myeloid leukemia.
Cancer 2008;112(1):4-16.
2008: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers.
Annals of hematology 2008;87(1):1-10.
2007: Claudia Haferlach; Frank Dicker; Susanne Schnittger; Wolfgang Kern; Torsten Haferlach
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping.
Leukemia 2007;21(12):2442-51.
2007: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
[Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
Medizinische Klinik (Munich, Germany : 1983) 2007;102(9):770-7.
2007: Frank Dicker; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach; Susanne Schnittger
Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.
Blood 2007;110(4):1308-16.
2007: Susanne Schnittger; Ulrike Bacher; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
Leukemia 2007;21(8):1843-5.
2007: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
Haematologica 2007;92(6):744-52.
2007: Ulrike Bacher; Torsten Haferlach; Wolfgang Kern; Hans-Detlev Harich; Susanne Schnittger; Claudia Haferlach
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Cancer genetics and cytogenetics 2007;175(1):52-6.
2007: Torsten Haferlach; Ulrike Bacher; Wolfgang Kern; Susanne Schnittger; Claudia Haferlach
Diagnostic pathways in acute leukemias: a proposal for a multimodal approach.
Annals of hematology 2007;86(5):311-27.
2007: Hannes Herholz; Wolfgang Kern; Susanne Schnittger; Torsten Haferlach; Frank Dicker; Claudia Haferlach
Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.
Cancer genetics and cytogenetics 2007;174(1):57-60.
2007: Susanne Schnittger; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Torsten Haferlach
Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Leukemia 2007;21(4):725-31.
2007: Torsten Haferlach; Ulrike Bacher; Claudia Haferlach; Wolfgang Kern; Susanne Schnittger
Insight into the molecular pathogenesis of myeloid malignancies.
Current opinion in hematology 2007;14(2):90-7.
2007: Torsten Haferlach; A Kohlmann; Ulrike Bacher; Susanne Schnittger; Claudia Haferlach; Wolfgang Kern
Gene expression profiling for the diagnosis of acute leukaemia.
British journal of cancer 2007;96(4):535-40.
2007: Susanne Schnittger; Ulrike Bacher; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML.
Leukemia 2007;21(1):183-4.
2006: Torsten Haferlach; Ulrike Bacher; Alexander Kohlmann; Susanne Schnittger; Wolfgang Kern; Claudia Haferlach
[Microarrays and gene expression profiling for the diagnosis in leukemia. From research studies to routine application].
Medizinische Klinik (Munich, Germany : 1983) 2006;101(11):908-14.
2006: Wolfgang Kern; Alexander Kohlmann; Claudia Schoch; Susanne Schnittger; Torsten Haferlach
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias.
Cancer 2006;107(10):2401-7.
2006: Wolfgang Kern; Elihu H Estey
High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.
Cancer 2006;107(1):116-24.